Navigation Links
Perrigo Company Announces Launch of Clobetasol Propionate Foam
Date:3/20/2008

ALLEGAN, Mich., March 20 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary injunction related to Perrigo's Clobetasol Propionate Foam, the AB-rated generic equivalent to Connetics' Olux(R) Foam and has lifted the temporary restraints that have prevented Perrigo from launching the product. The Court also denied Perrigo's motion for Summary Judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set.

With the temporary restraints lifted, Perrigo has commenced launching the product. As the first filer, this commences its 180 days of generic exclusivity.

Perrigo's Chairman and CEO Joseph C. Papa stated, "We are excited about the launch of Clobetasol Foam, which reflects our on-going efforts to make quality healthcare more affordable for our customers."

Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. Sales for the brand, Olux(R) Foam, 0.05%, were approximately $85 million according to Wolters Kluwer data for the 12 months ending January 2008.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... According to an article published ... a massive role in oral health and hygiene. The article points out that, as long ... on their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... aggression and sexual objectification, according to Georgia State University researchers. , ... girls in the fifth, sixth and seventh grades shared their experiences with ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State ... discriminated minorities’ quality of life and is currently focusing on ways to improve ... to be tested through research to find out whether watching them could have ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... provider of distance education worldwide for people who are blind or visually impaired, ... 10-year tenure of retiring President Charles E. Young. Hadley’s Board of Trustees retained ...
(Date:5/23/2016)... ... 23, 2016 , ... Overweight and obesity in children can be hard on ... most of all, it can be hard on the child carrying excess weight. And ... a dint in childhood obesity statistics or making it easier for overweight children to ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
(Date:5/23/2016)... SAN FRANCISCO , May 23, 2016 ... expected to reach USD 5.0 billion by 2022, according ... The increasing generation of medical waste coupled with the ... healthcare industry is expected to drive the demand for ... with these devices as compared to that of the ...
(Date:5/20/2016)... YORK , May 20, 2016 ... many veteran investors believe that the industry is not ... space, and today ActiveWallSt.com featured the following four equities: ... Inc. (NASDAQ: ATHX ), Aralez Pharmaceuticals Inc. ... (NASDAQ: INFI ). Sign up for your ...
Breaking Medicine Technology: